Cargando…

Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome

Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4(+) T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehen...

Descripción completa

Detalles Bibliográficos
Autores principales: Caprini, Elisabetta, Bresin, Antonella, Cristofoletti, Cristina, Helmer Citterich, Mauro, Tocco, Valeria, Scala, Enrico, Monopoli, Alessandro, Benucci, Roberto, Narducci, Maria Grazia, Russo, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281581/
https://www.ncbi.nlm.nih.gov/pubmed/30518749
http://dx.doi.org/10.1038/s41419-018-1212-7
_version_ 1783378841310330880
author Caprini, Elisabetta
Bresin, Antonella
Cristofoletti, Cristina
Helmer Citterich, Mauro
Tocco, Valeria
Scala, Enrico
Monopoli, Alessandro
Benucci, Roberto
Narducci, Maria Grazia
Russo, Giandomenico
author_facet Caprini, Elisabetta
Bresin, Antonella
Cristofoletti, Cristina
Helmer Citterich, Mauro
Tocco, Valeria
Scala, Enrico
Monopoli, Alessandro
Benucci, Roberto
Narducci, Maria Grazia
Russo, Giandomenico
author_sort Caprini, Elisabetta
collection PubMed
description Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4(+) T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this heterogeneous group of tumors. Additional studies may increase the knowledge about the complex genetic etiology characterizing this lymphoma. We used SNP6 arrays and GISTIC algorithm to prioritize a list of focal somatic copy-number alterations in a dataset of multiple sequential samples from 21 Sézary syndrome patients. Our results confirmed a prevalence of significant focal deletions over amplifications: single well-known tumor suppressors, such as TP53, PTEN, and RB1, are targeted by these aberrations. In our cohort, ZEB1 (TCF8, ZFHX1A) spans a deletion having the highest level of significance. In a larger group of 43 patients, we found that ZEB1 is affected by deletions and somatic inactivating mutations in 46.5% of cases; also, we found potentially relevant ZEB1 germline variants. The survival analysis shows a worse clinical course for patients with ZEB1 biallelic inactivation. Multiple abnormal expression signatures were found associated with ZEB1 depletion in Sézary patients we verified that ZEB1 exerts a role in oxidative response of Sézary cells. Our data confirm the importance of deletions in the pathogenesis of cutaneous T-cell lymphoma. The characterization of ZEB1 abnormalities in Sézary syndrome fulfils the criteria of a canonical tumor suppressor gene. Although additional confirmations are needed, our findings suggest, for the first time, that ZEB1 germline variants might contribute to the risk of developing this disease. Also, we provide evidence that ZEB1 activity in Sézary cells, influencing the reactive oxygen species production, affects cell viability and apoptosis.
format Online
Article
Text
id pubmed-6281581
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62815812018-12-06 Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome Caprini, Elisabetta Bresin, Antonella Cristofoletti, Cristina Helmer Citterich, Mauro Tocco, Valeria Scala, Enrico Monopoli, Alessandro Benucci, Roberto Narducci, Maria Grazia Russo, Giandomenico Cell Death Dis Article Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4(+) T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this heterogeneous group of tumors. Additional studies may increase the knowledge about the complex genetic etiology characterizing this lymphoma. We used SNP6 arrays and GISTIC algorithm to prioritize a list of focal somatic copy-number alterations in a dataset of multiple sequential samples from 21 Sézary syndrome patients. Our results confirmed a prevalence of significant focal deletions over amplifications: single well-known tumor suppressors, such as TP53, PTEN, and RB1, are targeted by these aberrations. In our cohort, ZEB1 (TCF8, ZFHX1A) spans a deletion having the highest level of significance. In a larger group of 43 patients, we found that ZEB1 is affected by deletions and somatic inactivating mutations in 46.5% of cases; also, we found potentially relevant ZEB1 germline variants. The survival analysis shows a worse clinical course for patients with ZEB1 biallelic inactivation. Multiple abnormal expression signatures were found associated with ZEB1 depletion in Sézary patients we verified that ZEB1 exerts a role in oxidative response of Sézary cells. Our data confirm the importance of deletions in the pathogenesis of cutaneous T-cell lymphoma. The characterization of ZEB1 abnormalities in Sézary syndrome fulfils the criteria of a canonical tumor suppressor gene. Although additional confirmations are needed, our findings suggest, for the first time, that ZEB1 germline variants might contribute to the risk of developing this disease. Also, we provide evidence that ZEB1 activity in Sézary cells, influencing the reactive oxygen species production, affects cell viability and apoptosis. Nature Publishing Group UK 2018-12-05 /pmc/articles/PMC6281581/ /pubmed/30518749 http://dx.doi.org/10.1038/s41419-018-1212-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Caprini, Elisabetta
Bresin, Antonella
Cristofoletti, Cristina
Helmer Citterich, Mauro
Tocco, Valeria
Scala, Enrico
Monopoli, Alessandro
Benucci, Roberto
Narducci, Maria Grazia
Russo, Giandomenico
Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title_full Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title_fullStr Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title_full_unstemmed Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title_short Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
title_sort loss of the candidate tumor suppressor zeb1 (tcf8, zfhx1a) in sézary syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281581/
https://www.ncbi.nlm.nih.gov/pubmed/30518749
http://dx.doi.org/10.1038/s41419-018-1212-7
work_keys_str_mv AT caprinielisabetta lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT bresinantonella lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT cristofoletticristina lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT helmercitterichmauro lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT toccovaleria lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT scalaenrico lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT monopolialessandro lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT benucciroberto lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT narduccimariagrazia lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome
AT russogiandomenico lossofthecandidatetumorsuppressorzeb1tcf8zfhx1ainsezarysyndrome